ZimVie (ZIMV) Q2 EPS Doubles to $0.26
ZimVie (NASDAQ:ZIMV), a medical technology company focused on dental implant systems, released its earnings results on July 30, 2025. The company reported a clear improvement in profitability, with adjusted diluted EPS of $0.26 -- beating the consensus estimate of $0.21 (non-GAAP). Revenue (GAAP) was $116.7 million, a decrease of (0.1)% from Q2 2024, just under last year but higher than expected. Revenue held steady at $116.7 million, representing a small decline of (0.1)% from Q2 2024, but beat forecasts by $3.9 million (3.4%). While total sales held steady, ZimVie posted a smaller net loss and a higher adjusted EBITDA margin compared to the prior year. The quarter showed progress on cost management and operational efficiency, even as market conditions remained slow.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
ZimVie is a dental technology firm specializing in dental implant systems, biomaterials (materials used to regenerate bone and soft tissue), and digital dentistry solutions such as surgical planning and workflow software. Following the sale of its spine business, the company has focused resources exclusively on dental markets, aiming to grow in faster-expanding segments by leveraging innovation and a broad catalog of products. Its primary customers are dental professionals globally, served through a combination of direct sales teams and specialized distributor partners.
Source Fool.com
